Benefit and risk associated with interleukin-6 receptor inhibitor administration during severe COVID-19: a retrospective multicentric study

C Charlène Lefèvre T Théo Funck-Brentano M Marine Cachanado A Alexia Plocque M Maëlle Youinou A Audrey Fels F Frédéric Pène (Université Paris Cité, CNRS UMR 8104, Inserm U1016) L Laurent Savale (INSERM, UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies (HPPIT)) D David Montani O Olivier Voisin F Flore Bintein L Lucille Wildenberg A Axel Philippe S Stephane Legriel N Nicolas Roche P Pierre-Regis Burgel (Université Paris Cité, CNRS UMR 8104, Inserm U1016) M Marc Tran N Nicolas Noel C Christophe Baillard J Jacques Duranteau G Gilles Chatellier F Francois Philippart

Article Details

Volume / Issue Vol. 16, Issue 1
Published January 22, 2026
ISSN 2045-2322
Publisher Nature Portfolio

Journal Info

Scientific Reports

Nature Portfolio

ISSN: 2045-2322 Open Access Life Sciences

Authors (22)

C

Charlène Lefèvre

T

Théo Funck-Brentano

M

Marine Cachanado

A

Alexia Plocque

M

Maëlle Youinou

A

Audrey Fels

F

Frédéric Pène

Université Paris Cité, CNRS UMR 8104, Inserm U1016

L

Laurent Savale

INSERM, UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies (HPPIT)

D

David Montani

O

Olivier Voisin

F

Flore Bintein

L

Lucille Wildenberg

A

Axel Philippe

S

Stephane Legriel

N

Nicolas Roche

P

Pierre-Regis Burgel

Université Paris Cité, CNRS UMR 8104, Inserm U1016

M

Marc Tran

N

Nicolas Noel

C

Christophe Baillard

J

Jacques Duranteau

G

Gilles Chatellier

F

Francois Philippart